KeyNeurotek generates $11M in series C financing
KeyNeurotek Pharmaceuticals AG, a German biotechnology company, has closed a series C financing round, generating around 8.2 million euros ($10.9 million).
All existing main investors, DVC Deutsche Venture Capital, IBG Beteiligungsgesellschaft and KfW have participated in this round. DVC acted as lead investor. Jurgen Gerlach, managing partner of the firm, has replaced Alexander Asam on KeyNeurotek's supervisory board.
The funds are being used to advance KeyNeurotek's diversified clinical product portfolio addressing major and unmet medical needs such as traumatic brain injury and urinary incontinence. The company's lead compound, KN38-7271, is a dual cannabinoid CB1/CB2 receptor agonist currently being investigated in a multinational Phase-IIa study in comatose TBI patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze